Comparative Pharmacology
Head-to-head clinical analysis: VERELAN versus VERELAN PM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VERELAN versus VERELAN PM.
VERELAN vs VERELAN PM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Verapamil inhibits calcium ion influx across cardiac and smooth muscle cells, blocking L-type calcium channels, leading to vasodilation and negative chronotropic, dromotropic, and inotropic effects.
Verapamil is a calcium channel blocker that inhibits the influx of calcium ions across the cardiac and vascular smooth muscle cells, thereby reducing myocardial contractility, sinoatrial and atrioventricular node conduction, and vascular tone.
Hypertension: 120-240 mg ER orally once daily; maximum 480 mg/day. Angina: 80-120 mg IR orally three times daily; ER 180-360 mg once daily.
Verelan PM (verapamil hydrochloride) is an extended-release oral capsule administered once daily at bedtime. Typical adult dose for hypertension is 200 mg to 400 mg once daily at bedtime. Initial dose is 200 mg, titrated upward as needed. Maximum recommended dose is 400 mg daily.
None Documented
None Documented
Terminal elimination half-life is 2.8 to 7.4 hours in healthy adults, prolonged in hepatic impairment or elderly (up to 12 hours).
Terminal elimination half-life 7.2 ± 1.5 hours after oral administration, prolonged in hepatic impairment (up to 14-16 hours) and elderly; steady-state achieved after 3-4 days.
Renal excretion accounts for approximately 70% of elimination, with 3-4% as unchanged drug. Fecal elimination accounts for about 25%, predominantly via biliary secretion.
Primarily hepatic metabolism (>95%), with 3-4% excreted unchanged in urine; biliary/fecal excretion accounts for <1% of unchanged drug.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker